QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
QQQ   267.85 (-0.91%)
AAPL   440.30 (-2.36%)
MSFT   204.98 (-1.57%)
FB   260.12 (-1.10%)
GOOGL   1,494.53 (-0.15%)
AMZN   3,106.98 (-1.31%)
NVDA   436.12 (-2.35%)
CGC   17.32 (-3.40%)
BABA   248.69 (+0.23%)
TSLA   1,379.00 (-2.79%)
GE   6.73 (+0.75%)
MU   48.53 (-1.26%)
AMD   77.28 (-6.03%)
T   30.45 (+0.83%)
F   7.25 (+2.26%)
ACB   10.13 (-0.98%)
GILD   68.12 (-0.57%)
NFLX   471.39 (-2.48%)
DIS   130.93 (+1.66%)
BAC   27.05 (+1.85%)
BA   182.12 (+1.51%)
Log in

NASDAQ:ONCESpark Therapeutics Stock Price, Forecast & News

$113.57
0.00 (0.00 %)
(As of 12/26/2019)
Add
Compare
Today's Range
$113.57
Now: $113.57
$113.57
50-Day Range
$113.57
MA: $113.57
$113.57
52-Week Range
$34.53
Now: $113.57
$114.20
Volume8,720 shs
Average Volume419,933 shs
Market Capitalization$4.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.05
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Read More
Spark Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.07 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$64.72 million
Book Value$13.15 per share

Profitability

Net Income$-78,820,000.00
Net Margins-358.41%

Miscellaneous

Employees368
Market Cap$4.37 billion
Next Earnings DateN/A
OptionableOptionable
$113.57
0.00 (0.00 %)
(As of 12/26/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

How has Spark Therapeutics' stock price been impacted by COVID-19?

Spark Therapeutics' stock was trading at $113.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONCE shares have increased by 0.0% and is now trading at $113.57.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Spark Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Spark Therapeutics
.

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.34. The biotechnology company had revenue of $25.19 million for the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative net margin of 358.41% and a negative return on equity of 59.10%.
View Spark Therapeutics' earnings history
.

What price target have analysts set for ONCE?

2 brokers have issued 12-month price targets for Spark Therapeutics' stock. Their forecasts range from $114.50 to $114.50. On average, they expect Spark Therapeutics' stock price to reach $114.50 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price.
View analysts' price targets for Spark Therapeutics
.

Has Spark Therapeutics been receiving favorable news coverage?

News headlines about ONCE stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Spark Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Spark Therapeutics
.

Who are some of Spark Therapeutics' key competitors?

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Brainstorm Cell Therapeutics (BCLI), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Intel (INTC) and Pfizer (PFE).

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the following people:
  • Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
  • Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
  • Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $113.57.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $4.37 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.

What is Spark Therapeutics' official website?

The official website for Spark Therapeutics is www.sparktx.com.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.